DossierENTITY

obinutuzumab

Coverage of obinutuzumab in the Nexus archive.

Earliest in view: Jun 5 · 16:55 UTCMost recent: Jun 5 · 16:55 UTC

Co-mentioned in this coverage

Recent coverage

HEALTHJun 5 · 16:55 UTCMEDPAGE TODAY
B-Cell Depleter Nabs Phase III Win in Autoimmune Kidney Disease
The B-cell depleting agent obinutuzumab (Gazyva) was superior to the immunosuppressant tacrolimus in inducing remissions in primary membranous nephropathy, according to the global phase III MAJESTY trial. By week 104, 37% of patients achieved remission.